Moleculin Biotech, Inc. 8-K

What Happened
Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on June 5, 2026 (Item 7.01) to disclose a press release announcing results from an independent market landscape assessment evaluating its drug candidate Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML). The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: June 5, 2026 (Form 8-K, Item 7.01 Regulation FD Disclosure).
• Topic disclosed: results of an independent market landscape assessment for Annamycin in R/R AML.
• Supporting document: Press Release dated June 5, 2026 included as Exhibit 99.1.
• Administrative exhibit filing: Cover page interactive XBRL file submitted (Item 9.01).

Why It Matters
The company publicly shared third‑party market assessment results about Annamycin’s commercial opportunity in R/R AML, which may provide investors new context on patient population, competitive landscape, or potential market size. Retail investors should review the attached press release (Exhibit 99.1) for the specific findings and metrics that could influence perceptions of Annamycin’s commercial prospects and the company’s development strategy.